BioSpace News Archive

Pieris Pharmaceuticals, Inc. announced the presentation of preclinical data from the Company’s inhaled connective tissue growth factor antagonist program, PRS-220, for idiopathic pulmonary fibrosis at the annual American Thoracic Society International Conference being held in Washington, D.C. May 19-24, 2023.

Apnimed presented positive results from the MARIPOSA Phase 2b trial, an efficacy, safety and dose-finding study of AD109 over a one-month duration, for the first time in the Breaking News in OSA Mini Symposium at the ATS 2023 International Conference in Washington, DC.

Positive Phase 3 results evaluating the investigational use of Dupixent® compared to placebo in adults currently on maximal standard-of-care inhaled therapy with uncontrolled chronic obstructive pulmonary disease and evidence of type 2 inflammation were shared in the 2023 American Thoracic Society International Conference session “New England Journal of Medicine and JAMA.

Nexcella, Inc. announced updated AL Amyloidosis clinical data from its ongoing Phase 1b/2a NEXICART-1 study of its novel, autologous, BCMA-targeted chimeric antigen receptor T cell therapy NXC-201 for the treatment of patients with relapsed or refractory multiple myeloma and light chain amyloidosis.

Laekna, a clinical-stage biotechnology company dedicated to bringing novel therapies to cancer and liver fibrosis patients worldwide, announced that the U.S. Food and Drug Administration has cleared the Investigational New Drug application of LAE102 antibody to initiate clinical development.

Immix Biopharma, Inc., announced updated AL Amyloidosis clinical data from its ongoing Phase 1b/2a NEXICART-1 study of its novel, autologous, BCMA-targeted chimeric antigen receptor T cell therapy NXC-201 for the treatment of patients with relapsed or refractory multiple myeloma and light chain amyloidosis.

Regeneron Pharmaceuticals, Inc. and Sanofi presented positive Phase 3 results evaluating the investigational use of Dupixent® compared to placebo in adults currently on maximal standard-of-care inhaled therapy with uncontrolled chronic obstructive pulmonary disease and evidence of type 2 inflammation.

BioArctic AB’s partner Eisai announced that they have submitted a Marketing Authorisation Application for lecanemab, an investigational anti-amyloid beta protofibril antibody, for the treatment of early Alzheimer’s disease with confirmed amyloid pathology in the brain, to the UK Medicines and Healthcare products Regulatory Agency in Great Britain.